Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

Summary

Nona Biosciences and Lonza announced a strategic collaboration to develop single-domain antibody-based technology for blood-brain barrier crossing in CNS disease treatments. The partnership aims to advance best-in-class therapeutic solutions in neurology.